227 related articles for article (PubMed ID: 35117267)
1. Neoadjuvant chemotherapy for upper tract urothelial carcinoma.
Kim DK; Cho KS
Transl Cancer Res; 2020 Oct; 9(10):6576-6582. PubMed ID: 35117267
[TBL] [Abstract][Full Text] [Related]
2. Neoadjuvant and Adjuvant Chemotherapy for Upper Tract Urothelial Carcinoma: A 2020 Systematic Review and Meta-analysis, and Future Perspectives on Systemic Therapy.
Leow JJ; Chong YL; Chang SL; Valderrama BP; Powles T; Bellmunt J
Eur Urol; 2021 May; 79(5):635-654. PubMed ID: 32798146
[TBL] [Abstract][Full Text] [Related]
3. Efficacy of neoadjuvant and adjuvant chemotherapy for localized and locally advanced upper tract urothelial carcinoma: a systematic review and meta-analysis.
Quhal F; Mori K; Sari Motlagh R; Laukhtina E; Pradere B; Rouprêt M; Necchi A; Moschini M; Shariat SF
Int J Clin Oncol; 2020 Jun; 25(6):1037-1054. PubMed ID: 32206939
[TBL] [Abstract][Full Text] [Related]
4. National trends in clinical and pathologic staging for upper tract urothelial carcinoma: Implications for neoadjuvant chemotherapy.
Rodrigues Pessoa R; Morrison JC; Konety B; Gershman B; Maroni P; Kukreja JB; Cost N; Flaig T; Kessler E; Sharma P; Kim SP
Urol Oncol; 2021 Dec; 39(12):832.e9-832.e15. PubMed ID: 33820697
[TBL] [Abstract][Full Text] [Related]
5. Trends in the use of neoadjuvant chemotherapy and oncological outcomes for high-risk upper tract urothelial carcinoma: a multicentre retrospective study.
Hamaya T; Hatakeyama S; Tanaka T; Kubota Y; Togashi K; Hosogoe S; Fujita N; Kusaka A; Tokui N; Okamoto T; Yamamoto H; Yoneyama T; Yoneyama T; Hashimoto Y; Ohyama C
BJU Int; 2021 Oct; 128(4):468-476. PubMed ID: 33484231
[TBL] [Abstract][Full Text] [Related]
6. Effect of neoadjuvant chemotherapy on locally advanced upper tract urothelial carcinoma: a pooled analysis.
Qiu D; Hu J; He T; Li H; Hu J; Yi Z; Chen J; Zu X
Transl Androl Urol; 2020 Oct; 9(5):2094-2106. PubMed ID: 33209672
[TBL] [Abstract][Full Text] [Related]
7. Effect of neoadjuvant chemotherapy on locally advanced upper tract urothelial carcinoma: A systematic review and meta-analysis.
Kim DK; Lee JY; Kim JW; Hah YS; Cho KS
Crit Rev Oncol Hematol; 2019 Mar; 135():59-65. PubMed ID: 30819447
[TBL] [Abstract][Full Text] [Related]
8. Oncologic Outcomes in Patients with Residual Upper Tract Urothelial Carcinoma Following Neoadjuvant Chemotherapy.
Fletcher SA; Pallauf M; Watts EK; Lombardo KA; Campbell JA; Rezaee ME; Rouprêt M; Boorjian SA; Potretzke AM; Roshandel MR; Ploussard G; Djaladat H; Ghoreifi A; Mari A; Campi R; Khene ZE; Raman JD; Kikuchi E; Rink M; Abdollah F; Boormans JL; Fujita K; D'Andrea D; Soria F; Breda A; Hoffman-Censits J; McConkey DJ; Shariat SF; Pradere B; Singla N
Eur Urol Oncol; 2024 Jan; ():. PubMed ID: 38262800
[TBL] [Abstract][Full Text] [Related]
9. Perioperative chemotherapy in upper tract urothelial carcinoma: a comprehensive review.
Aziz A; Dobruch J; Hendricksen K; Kluth LA; Necchi A; Noon A; Rink M; Roghmann F; Seiler R; Gontero P; Kassouf W; Shariat SF; Xylinas E;
World J Urol; 2017 Sep; 35(9):1401-1407. PubMed ID: 28074261
[TBL] [Abstract][Full Text] [Related]
10. Contemporary Trends of Systemic Neoadjuvant and Adjuvant Intravesical Chemotherapy in Patients With Upper Tract Urothelial Carcinomas Undergoing Minimally Invasive or Open Radical Nephroureterectomy: Analysis of US Claims on Perioperative Outcomes and Health Care Costs.
Del Giudice F; van Uem S; Li S; Vilson FL; Sciarra A; Salciccia S; Busetto GM; Maggi M; Tiberia L; Viscuso P; Canale V; Panebianco V; Pecoraro M; Ferro M; Moschini M; Krajewski W; D'Andrea D; Cacciamani GE; Mari A; Soria F; Porpiglia F; Fiori C; Amparore D; Checcucci E; Autorino R; De Berardinis E; Chung BI
Clin Genitourin Cancer; 2022 Apr; 20(2):198.e1-198.e9. PubMed ID: 35031226
[TBL] [Abstract][Full Text] [Related]
11. Overview, Diagnosis, and Perioperative Systemic Therapy of Upper Tract Urothelial Carcinoma.
Kolawa A; D'Souza A; Tulpule V
Cancers (Basel); 2023 Sep; 15(19):. PubMed ID: 37835507
[TBL] [Abstract][Full Text] [Related]
12. Oncological Outcomes of Laparoscopic Nephroureterectomy Versus Open Radical Nephroureterectomy for Upper Tract Urothelial Carcinoma: An European Association of Urology Guidelines Systematic Review.
Peyronnet B; Seisen T; Dominguez-Escrig JL; Bruins HM; Yuan CY; Lam T; Maclennan S; N'dow J; Babjuk M; Comperat E; Zigeuner R; Sylvester RJ; Burger M; Mostafid H; van Rhijn BWG; Gontero P; Palou J; Shariat SF; Roupret M
Eur Urol Focus; 2019 Mar; 5(2):205-223. PubMed ID: 29154042
[TBL] [Abstract][Full Text] [Related]
13. Oncological outcomes of neoadjuvant chemotherapy in patients with locally advanced upper tract urothelial carcinoma: a multicenter study.
Kubota Y; Hatakeyama S; Tanaka T; Fujita N; Iwamura H; Mikami J; Yamamoto H; Tobisawa Y; Yoneyama T; Yoneyama T; Hashimoto Y; Koie T; Ito H; Yoshikawa K; Sasaki A; Kawaguchi T; Ohyama C
Oncotarget; 2017 Nov; 8(60):101500-101508. PubMed ID: 29254181
[TBL] [Abstract][Full Text] [Related]
14. Impact of neoadjuvant chemotherapy on survival prognosis and pathological downstaging in patients presenting with high-risk upper tract urothelial carcinoma: A protocol for systematic review and meta analysis.
Li K; Xie W; Gao L; Huang G; Zhou J; Mei B; Chen J
Medicine (Baltimore); 2020 May; 99(18):e20184. PubMed ID: 32358407
[TBL] [Abstract][Full Text] [Related]
15. Pre-therapy serum albumin-to-globulin ratio in patients treated with neoadjuvant chemotherapy and radical nephroureterectomy for upper tract urothelial carcinoma.
Pradere B; D'Andrea D; Schuettfort VM; Foerster B; Quhal F; Mori K; Abufaraj M; Margulis V; Deuker M; Briganti A; Muilwijk T; Hendricksen K; Lotan Y; Karakiewic P; F Shariat S;
World J Urol; 2021 Jul; 39(7):2567-2577. PubMed ID: 33067726
[TBL] [Abstract][Full Text] [Related]
16. Neoadjuvant Chemotherapy before Nephroureterectomy in High-Risk Upper Tract Urothelial Cancer: A Systematic Review and Meta-Analysis.
Oswald D; Pallauf M; Deininger S; Törzsök P; Sieberer M; Eiben C
Cancers (Basel); 2022 Oct; 14(19):. PubMed ID: 36230764
[TBL] [Abstract][Full Text] [Related]
17. Outcomes of subsequent non-muscle-invasive bladder cancer treated with intravesical Bacillus Calmette-Guérin after radical nephroureterectomy for upper urinary tract urothelial carcinoma.
Miyake M; Tatsumi Y; Matsumoto H; Nagao K; Matsuyama H; Inamoto T; Azuma H; Yasumoto H; Shiina H; Fujimoto K;
BJU Int; 2018 May; 121(5):764-773. PubMed ID: 29281857
[TBL] [Abstract][Full Text] [Related]
18. The clinicopathological characteristics of muscle-invasive bladder recurrence in upper tract urothelial carcinoma.
Shigeta K; Matsumoto K; Ogihara K; Murakami T; Anno T; Umeda K; Izawa M; Baba Y; Sanjo T; Shojo K; Tanaka N; Takeda T; Kosaka T; Mizuno R; Mikami S; Kikuchi E; Oya M
Cancer Sci; 2021 Mar; 112(3):1084-1094. PubMed ID: 33368857
[TBL] [Abstract][Full Text] [Related]
19. Ureteroscopic and percutaneous management of upper tract urothelial carcinoma (UTUC): systematic review.
Cutress ML; Stewart GD; Zakikhani P; Phipps S; Thomas BG; Tolley DA
BJU Int; 2012 Sep; 110(5):614-28. PubMed ID: 22471401
[TBL] [Abstract][Full Text] [Related]
20. Impact of renal function on eligibility for chemotherapy and survival in patients who have undergone radical nephro-ureterectomy.
Xylinas E; Rink M; Margulis V; Clozel T; Lee RK; Comploj E; Novara G; Raman JD; Lotan Y; Weizer A; Roupret M; Pycha A; Scherr DS; Seitz C; Ficarra V; Trinh QD; Karakiewicz PI; Montorsi F; Zerbib M; Shariat SF;
BJU Int; 2013 Aug; 112(4):453-61. PubMed ID: 23464979
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
